The Impact of the SARS-Cov2 Pandemic on a Persuasive Educational Antimicrobial Stewardship Program in a University Hospital in Southern Italy: A Pre-Post Study
Overview
Authors
Affiliations
Objectives: We evaluated the effect of the pandemic on the disruption of a persuasive educational antimicrobial stewardship program (ASP) conducted in a university hospital in southern Italy.
Methods: In March 2020, the ASP, which began in January 2017 and was carried out at different times in 10 wards, was stopped due to the COVID-19 pandemic. We conducted an observational study with interrupted time series analysis to compare the antibiotic consumption and costs, average length of hospital stay and in-hospital mortality between 12 months before and 9 months after the interruption.
Results: Four medical, four surgical wards and two ICUs were included in the study, for a total of 35,921 patient days. Among the medical wards we observed after the interruption a significant increase in fluoroquinolone use, with a change in trend (CT) of 0.996, = 0.027. In the surgical wards, we observed a significant increase in the overall consumption, with a change in level (CL) of 24.4, = 0.005, and in the use of third and fourth generation cephalosporins (CL 4.7, = 0.003). In two ICUs, we observed a significant increase in piperacillin/tazobactam and fluoroquinolone consumption (CT 9.28, = 0.019, and 2.4, = 0.047). In the wards with a duration of ASP less than 30 months, we observed a significant increase in antibiotic consumption in the use of piperacillin/tazobactam and fluoroquinolones (CT 12.9, = 0.022: 4.12, = 0.029; 1.004, = 0.011).
Conclusions: The interruption of ASP during COVID-19 led to an increase in the consumption of broad-spectrum antibiotics, particularly in surgical wards and in those with a duration of ASP less than 30 months.
Ji W, Zhao Y, Du J, Zhao H, McIver D, Ye D Front Public Health. 2025; 13:1475207.
PMID: 40046123 PMC: 11880026. DOI: 10.3389/fpubh.2025.1475207.
Ng R, Yang L, Lau S, Hawkey P, Ip M JAC Antimicrob Resist. 2025; 7(1):dlaf001.
PMID: 39866328 PMC: 11759295. DOI: 10.1093/jacamr/dlaf001.
Zaha D, Ilea C, Dorobantu F, Pantis C, Pop O, Dascal D Antibiotics (Basel). 2024; 13(6).
PMID: 38927144 PMC: 11200525. DOI: 10.3390/antibiotics13060477.
Impact of COVID-19 on antimicrobial stewardship activities in Italy: a region-wide assessment.
Vicentini C, Corcione S, Moro G, Mara A, De Rosa F, Zotti C Antimicrob Resist Infect Control. 2024; 13(1):48.
PMID: 38725026 PMC: 11084085. DOI: 10.1186/s13756-024-01407-3.
Analysis of Changes in Antibiotic Use Patterns in Korean Hospitals during the COVID-19 Pandemic.
Kim B, Hwang H, Chae J, Kim Y, Kim D Antibiotics (Basel). 2023; 12(2).
PMID: 36830109 PMC: 9952207. DOI: 10.3390/antibiotics12020198.